Head-To-Head Comparison: Pharmacyte Biotech (PMCB) & Heska (HSKA)

Pharmacyte Biotech (OTCMKTS:PMCB) and Heska (NASDAQ:HSKA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.

Insider and Institutional Ownership

0.2% of Pharmacyte Biotech shares are held by institutional investors. Comparatively, 83.0% of Heska shares are held by institutional investors. 14.0% of Heska shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Pharmacyte Biotech and Heska’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pharmacyte Biotech N/A -74.36% -66.54%
Heska 3.63% 8.36% 6.48%

Risk and Volatility

Pharmacyte Biotech has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Heska has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.

Earnings & Valuation

This table compares Pharmacyte Biotech and Heska’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pharmacyte Biotech N/A N/A -$6.82 million N/A N/A
Heska $127.45 million 4.79 $5.85 million $1.42 55.52

Heska has higher revenue and earnings than Pharmacyte Biotech.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Pharmacyte Biotech and Heska, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharmacyte Biotech 0 0 0 0 N/A
Heska 0 3 1 0 2.25

Heska has a consensus target price of $108.33, indicating a potential upside of 37.41%. Given Heska’s higher probable upside, analysts plainly believe Heska is more favorable than Pharmacyte Biotech.

Summary

Heska beats Pharmacyte Biotech on 9 of the 10 factors compared between the two stocks.

About Pharmacyte Biotech

PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. Heska Corporation sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.

Receive News & Ratings for Pharmacyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmacyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.